Abstract
The blaIMP-14 carbapenem resistance gene has largely previously been observed in Pseudomonas aeruginosa and Acinetobacter spp. As part of global surveillance and sequencing of carbapenem-resistant Escherichia coli, we identified a sequence type 131 strain harboring blaIMP-14 within a class 1 integron, itself nested within an ∼54-kb multidrug resistance region on an epidemic IncA/C2 plasmid. The emergence of blaIMP-14 in this context in the ST131 lineage is of potential clinical concern.
Highlights
The emergence of carbapenemases in clinically prevalent Escherichia coli lineages, such as sequence type (ST) 131, is a major problem for the management of patients infected by these strains[1, 2]
Associations of blaIMP with E. coli ST131 have to date been restricted to blaIMP-4 and blaIMP-8 in Taiwan, China and Australia[8,9,10,11]
As part of the Merck Study for Monitoring Antimicrobial Resistance Trends (SMART)(1), we identified an IMP-14-producing ST131 E. coli isolate, Ecol_732, from Bangkok, Thailand, isolated in 2012, which was sequenced in order to ascertain the genetic structures associated with this IMP variant in ST131
Summary
The emergence of carbapenemases in clinically prevalent Escherichia coli lineages, such as sequence type (ST) 131, is a major problem for the management of patients infected by these strains[1, 2]. An IMP metallo-beta-lactamase enzyme (IMP-1) was first detected in Japan in Pseudomonas aeruginosa in the late 1980s(4); since 52 genetically diverse blaIMP gene variants 738-747bp in length have been identified[5].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call